DGAT1-IN-1_COA_13570_MedChemExpress

花生AhDGAT1 基因启动子的克隆与功能验证

花生AhDGAT1 基因启动子的克隆与功能验证张会;郑玲;万书波;李新国;郭峰;单雷;高文伟;彭振英【摘要】二酰基甘油酰基转移酶(DGAT)是三酰基甘油(TAG)生物合成过程的限速酶.在本研究中,通过染色体步移法从栽培花生品种鲁花14基因组中克隆了AhDGAT1的启动子(pAhDGAT1)序列,并通过生物信息学分析发现该启动子含有多个 TATA-box、CAAT-box、光调控元件、胁迫防御相关元件和激素响应元件.利用农杆菌介导法将pAhDGAT1∶GUS植物表达载体转化烟草叶片.通过GUS染色发现在转基因烟草营养器官和生殖器官中均检测到GUS表达,在花丝和花柱中表达较低,而在柱头、花药和种子中表达较高,表明pAhDGAT1表达没有组织特异性,具有组成型启动子的特征.%Diacylglycerol acyltransferase (DGAT) is a rate-limiting enzyme in the biosynthesis pathway of triacylglycerol (TAG).In this study, with peanut cultivar Luhua 14 as material, we cloned the promoter sequence of AhDGAT1 gene (pAhDGAT1) by genome walking method.By bioinformatics analysis, we found that the pAhDGAT1 had many TATA-box, CAAT-box, light regulation, stress and defense response and hormone response elements.The constructed pAhDGAT1∶GUS plant expression vector was transformed into tobacco leaves by Agrobacterium tumefaciens-mediated method.By GUS staining,we found the GUS enzyme activity were detected in all organs of the positive transgenic tobacco lines, while in stigma, anther and young seed, the expression levels were higher than those in filament and style.It indicated that pAhDGAT1 was not tissue-specific promoter and had constitutive promoter feature.【期刊名称】《山东农业科学》【年(卷),期】2017(049)007【总页数】7页(P1-6,11)【关键词】花生;AhDGAT1基因;启动子;GUS染色;功能验证【作者】张会;郑玲;万书波;李新国;郭峰;单雷;高文伟;彭振英【作者单位】新疆农业大学农学院,新疆乌鲁木齐 830000;山东大学生命科学学院,山东济南 250100;山东省农业科学院生物技术研究中心/山东省作物遗传改良与生态生理重点实验室,山东济南 250100;山东省农业科学院生物技术研究中心/山东省作物遗传改良与生态生理重点实验室,山东济南 250100;山东省农业科学院生物技术研究中心/山东省作物遗传改良与生态生理重点实验室,山东济南 250100;山东省农业科学院生物技术研究中心/山东省作物遗传改良与生态生理重点实验室,山东济南 250100;新疆农业大学农学院,新疆乌鲁木齐 830000;新疆农业大学农学院,新疆乌鲁木齐 830000;山东大学生命科学学院,山东济南 250100;山东省农业科学院生物技术研究中心/山东省作物遗传改良与生态生理重点实验室,山东济南250100【正文语种】中文【中图分类】S565.2;Q781我国花生不仅总产量在世界占据首位而且有近500万公顷的种植面积，是主要的油料和经济作物之一[1]。

CircBACH1调节miR-140-5p

Tianjin Med J,November2023,Vol.51No.11 CircBACH1调节miR-140-5p/MDM2轴对多发性骨髓瘤细胞增殖、凋亡和化疗敏感性的影响刘荟敏，许旋旋，王远丽，熊涛，唐元艳△摘要：目的探讨CircBACH1对多发性骨髓瘤（MM）细胞增殖、凋亡和化疗敏感性的影响以及在此过程中对miR-140-5p/MDM2轴的调节机制。

方法收集MM组和正常对照组骨髓浆细胞，将人MM细胞系U266细胞分为未转染（Control）组、si-NC组、si1-CircBACH1组、si2-CircBACH1组、si-CircBACH1+anti-miR-NC组、si-CircBACH1+ anti-miR-140-5p组。

实时荧光定量PCR检测细胞中CircBACH1、miR-140-5p、鼠双微体2（MDM2）mRNA的表达；CCK-8法检测细胞增殖活性；流式细胞术检测细胞凋亡及对硼替佐米的敏感性；Western blot检测细胞中B细胞淋巴因子2（Bcl-2）、Bcl-2相关X蛋白（Bax）、裂解的胱天蛋白酶（cleaved caspase）-3蛋白的表达；双萤光素酶报告基因实验验证CircBACH1、miR-140-5p、MDM2三者的靶向关系。

结果与正常对照组相比，MM组的骨髓浆细胞及U266细胞中CircBACH1、MDM2mRNA表达升高，miR-140-5p表达降低（P＜0.05）；与Control组和si-NC组相比，si-CircBACH1组细胞中CircBACH1、MDM2的mRNA表达、细胞增殖活性、Bcl-2蛋白表达均降低，miR-140-5p的表达、细胞凋亡率、化疗敏感性及cleaved caspase-3、Bax表达均升高（P＜0.05）；而回补实验中，si-CircBACH1对MM细胞的影响被anti-miR-140-5p逆转，且MDM2的表达也升高（P＜0.05）。

EDTA滴定法测定牛奶包装中碳酸钙的迁移

EDTA滴定法测定牛奶包装中碳酸钙的迁移马少华;秦志伟;卢金【摘要】根据GB/T 5009.92-2016,以水、20％乙醇、4％乙酸和正己烷作为食品模拟液,把牛奶塑料包装袋装入食品模拟液,以时间和温度为变量,蒸干浸泡后的模拟液后消解定容,然后以钙红作为指示剂,用EDTA滴定检测迁移出的碳酸钙的浓度.结果表明,牛奶塑料包装袋中的碳酸钙在不同的模拟液体中的迁移量与温度和时间的变化成正比.【期刊名称】《广州化学》【年(卷),期】2018(043)006【总页数】4页(P68-71)【关键词】纳米钙;食品模拟物;EDTA;塑料牛奶包装袋;迁移【作者】马少华;秦志伟;卢金【作者单位】宁波卫生职业技术学院,浙江宁波 315100;宁波卫生职业技术学院,浙江宁波 315100;宁波卫生职业技术学院,浙江宁波 315100【正文语种】中文【中图分类】T317.2以聚乙烯、聚丙烯等高分子材料制作的食品接触材料以其质轻、强度高、耐腐蚀等优良特性及低廉的价格为购物和生活带来了极大的便利。

但废弃的塑料薄膜或包装袋具有很高的稳定性，在自然界中难以迅速降解，造成了白色污染。

为解决这一问题，易老化、可降解的环境友好型塑料应运而生[1]。

目前，以纳米碳酸钙和聚乙烯、聚丙烯等高分子材料制作的复合材料已经广泛的用作食品接触材料，这类材料不但具有良好的加工性能和力学性能，而且容易降解。

因此，此类材料已经广泛用于制作牛奶简易包装袋、酸奶盒、酸奶袋、酸奶瓶、食品保鲜盒、食品购物袋等。

纳米材料在改善食品包装功能的同时，其安全性一直是消费者、研究人员、行业管理者高度关注的问题[2]。

目前，对食品接触材料中的纳米碳酸钙向食品中的迁移研究还不多。

GB/T 5009.92-2016《食品中钙的测定》中提供了火焰原子吸收光谱法、EDTA滴定法、电感耦合等离子体发射光谱法和电感耦合等离子体质谱法四种方法[3-4]。

除EDTA滴定法外，其它三种方法都需要用到大型仪器设备。

基于TCGA数据库分析GTSE1基因在肺腺癌中的表达及意义

论著文章编号１００６－８１４７（２０21）０3-0274-05作者简介高周勇(1994-)，男，硕士在读，研究方向：肺癌蛋白质组学；通信作者：王广舜，E-mail ：*******************。

基于TCGA 数据库分析GTSE1基因在肺腺癌中的表达及意义高周勇，张文成，王广舜（天津医科大学宝坻临床医学院肿瘤科，天津301800）摘要目的：探究G2/S 期表达蛋白1（G2and S phase-expressed protein1，GTSE1）在肺腺癌中的表达情况以及对预后的影响。

方法：从癌症基因组图谱（TCGA ）数据库中下载肺腺癌患者表达谱数据以及临床信息资料，分析GTSE1表达水平与临床指标信息之间的相关性及对预后的影响，并用Cox 比例风险回归模型分析影响患者预后的因素。

采用免疫组化检测14例肺腺癌肿瘤组织和13例癌旁组织中GTSE1表达水平。

采用基因集富集分析方法（GSEA ）预测GTSE1在肺腺癌中可能参与并调控的相关通路。

结果：在TCGA 数据中，在肿瘤组织样本中GTSE1基因表达情况明显高于正常组织（t =18.165，P <0.05），且表达水平与肿瘤分级（字2=17.543，P =0.001）、T （字2=8.825，P =0.032）和N 分期（字2=12.138，P =0.001）之间有显著相关，GTSE1高表达患者的总生存期显著低于GTSE1低表达的患者（字2=22.663，P <0.05），单因素Cox 分析提示肿瘤分级（HR =1.56，95%CI ：1.33～1.83）、TNM 分期（T ：HR =1.60，95%CI ：1.31～1.95；N ：HR =1.70，95%CI ：1.40～2.06；M ：HR =1.83，95%CI ：1.03～3.25）和GTSE1表达水平（HR =2.32，95%CI ：1.62～3.30）可影响患者的总生存期（均P <0.05）。

高效液相色谱法测定阿托伐他汀钙片有关物质

高效液相色谱法测定阿托伐他汀钙片有关物质作者：刘振宇来源：《科技创新与应用》2014年第26期摘要：采用高效液相色谱法对阿托伐他汀钙片有关物质进行检测，十八烷基硅烷键合硅胶为填充剂（250mm×4.6mm，5μm），流动相为0.05mol/L柠檬酸溶液（用氨水调节pH值至4.0）-乙腈-四氢呋喃（53：27：20），检测波长为244nm，柱温为35℃，流速为1.5mL/min。

结果表明，在所建立的色谱条件下，阿托伐他汀钙与各杂质分离良好，所建立的方法专属性、精密度、准确度、耐用性均较好，可用于阿托伐他汀钙片有关物质的测定。

关键词：阿托伐他汀钙片；有关物质；高效液相色谱法心血管疾病是危害人类健康（特别是中老年）最常见、最严重的疾病之一，血脂异常是动脉粥样硬化、冠心病以及其他心脑血管疾病的重要危险因素。

阿托伐他汀通过抑制肝脏内HMG-CoA还原酶和胆固醇的合成从而降低血浆中胆固醇和脂蛋白水平，并通过增加细胞表面的肝脏LDL受体以增强LDL的摄取和代谢。

医学界公认比天然微生物发酵、半合成的他汀类药物好，患者使用时，起始剂量即有优异的调脂达标率。

文章建立了以0.05mol/L柠檬酸溶液（用氨水调节pH值至4.0）-乙腈-四氢呋喃（53：27：20）为流动相的HPLC分析方法，用于对阿托伐他汀钙的测定[1-2]。

该方法专属性良好，而且方法方便、快速、准确。

1 材料1.1 仪器高效液相色谱仪（Hitachi Chromaster-5430检测器，Hitachi Chromaster-5310柱温箱，Hitachi Chromaster-5210自动进样器，Hitachi Chromaster-5110泵），Chromaster色谱工作站，日本Hitachi公司；十八烷基硅烷键合硅胶色谱柱（250mm×4.0mm，5μm），美国Thermo公司； AR1140电子天平，美国Ohaus公司。

阿托伐他汀钙纳米结构脂质载体对大_省略_肌缺血_再灌注损伤的保护作用研究_姜雪

= 0． 999 9）。可见阿托伐他汀钙在1． 0 ～ 20． 0 μg· ml － 1 浓度范围内线药物浓度与峰面积性关系良好。 2． 2 阿托伐他汀钙纳米结构脂质载体包封率的测
定
精密移取阿托伐他汀钙纳米结构脂质载体 0． 5 ml置于超滤离心管（截留相对分子质量： 10 000 道尔顿）上端，在离心速度为 5 000 r·min － 1 条件下离心处理 10 min，将滤液转移到 10 ml 量瓶中，加入乙腈溶解，定容；另精密移取阿托伐他汀钙纳米结构脂质载体 0． 5 ml 置 10 ml 量瓶中，加入乙腈超声（ 250 W，40 kHz）至溶液透明，定容。分别取上述两种溶液续滤液 HPLC 测定。按下式计算包封率（ EE）：
清洁级雄性 SD 大鼠（由徐州医学院实验动物中心提供，许可证号： JSJK（苏） -2012-008），6 ～ 8 周龄，体质量（ 220 ～ 250） g。 2 方法与结果 2． 1 方法学考察 2． 1． 1 色谱条件色谱柱： Hypersil ODS-C18 柱
（ 250 mm × 4． 6 mm，5 μm）；流动相：乙腈-0． 02 mol 獉L － 1 磷酸二氢钾（ 60 ∶ 40，用磷酸调 pH 至4． 0）；检测波长： 246 nm；流速： 1． 0 ml獉min － 1 ；柱温：室温；进样体积： 20 μl。 2． 1． 2 线性关系称取 10 mg 阿托伐他汀钙对照品置于 100 ml 量瓶中，加入少量乙腈振摇溶解，用流动相稀释至刻度，摇匀，作为对照品贮备液（ 100 μg·ml － 1 ）。精密量取对照品贮备液用流动相稀释成浓度为1． 0，2． 0，5． 0，10． 0，20． 0 μg·ml － 1 系列阿托伐他汀钙标准溶液，摇匀，滤过，精密移取各浓度对照品溶液 20 μl，按“2． 1． 1”项下色谱条件测定，记录色谱峰面积。以阿托伐他汀钙浓度（ C，μg · ml － 1 ）对峰面积（ A）作线性作最小二次方程回归拟合，得回归方程为： A = 4． 297 × 104 C － 3． 873 × 103 （ r

乙酰肝素酶－1／多配体蛋白聚糖－1轴对肝癌细胞侵袭能力的影响

乙酰肝素酶－1／多配体蛋白聚糖－1轴对肝癌细胞侵袭能力的影响于生金【摘要】Heparanase-1/Syndecan-1 axis mediates the metastasis of many types of tumors.The change in invasive ability of tumor cell is the key factor to induce the spread of tumor cells from primary lesions to distant sites.This study aims to detect the existence of Heparanase -1/syndecan -1 axis and the involved effects of Heparanase-1/syndecan-1 axis on invasive ability of hepatocarcinoma cell Hepa1-6.SDC-1 small interfering RNA and recombinant HPA-1 ( rHPA-1) were used to treat Hepa1-6 cells, and then SDC-1 expression was detected by RT-PCR, Western-blot and immunocytochemistry assays, and Matrigel invasion test was performed to observe the invasive ability.The results showed that SDC-1 small interfering RNA obviously inhibited SDC-1 expression; the treatment of rHPA -1 significantly down -regulated the molecule weight of SDC -1, but not changed the levels of SDC-1 mRNA;both SDC-1 knockdown and rHPA-1 treatment promoted the invasion of Hepa1-6 cells.In conclusion, HPA-1 induces the metastasis of hepatocarcinoma cell via acting on SDC-1 pro-tein.%乙酰肝素酶－1（ Heparanase－1， HPA－1）／多配体蛋白聚糖－1（ Syndecan－1， SDC－1）轴调控多种肿瘤细胞的转移。

Calcipotriol_SDS_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Sep.-13-2017Print Date:Sep.-13-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CalcipotriolCatalog No. :HY-10001CAS No. :112965-21-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MC 903; CalcipotrieneFormula:C27H40O3Molecular Weight:412.60CAS No. :112965-21-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: 4°C, protect from light, stored under nitrogenShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

细胞外基质金属蛋白酶诱导因子在肝癌细胞7721中对多药耐药的调节作用

ＰＩＲＮ的人肝癌多药耐药细胞７２／ｄ／Ｎｉ７２／ｄ／Ｎｉ７１ｍｌＡ和７１ｍ２ＲＡ细胞。用反转录一ＡＲＡ聚合酶链反应（ＴＰＲ）流Ｒ－Ｃ、式细胞技术检测ＥＭＭＰＩ细胞表面多药耐药基因（Ｒ１ｍＲＡ及其表达产物的表达水平。噻唑蓝（ｒ法ＲＮ、ＭＤ一）ＮＭＴ）检测上述各细胞的多药耐药性。结果２种多药耐药模型可用于肝癌多药耐药研究。多药耐药细胞７２／ｄ和７１ｍｌＡ７２／ｄ７１ｍ２中ＥＡＭＭＰＩＭＤ一ＲＮ，Ｒ１的表达水平较７２７１细胞均升高，且增加了其对多种化疗药物的耐药性。而利用
中国药物与临床２１年８０１月第１卷第８Ｃｉｓｅｅｉ＆Ｃｉｃ。ｕｕｔ０１ｏ１，ｏ１期ｈｅＲｍｄｅｎｅｓｌｉＡｇｓ２１，１ｌ．ｎｓＶ．Ｎ８
・８３・９
细胞外基质金属蛋白酶诱导因子在肝癌细胞７２７１中对多药耐药的调节作用
ｓｄｈｏｅｏＭＭＰＮｉｅｅｏｍｅｔｏｌｄｕ — ｅｉｔｎｅｆｔｙｔｅｒｌｆＥｕＲＩｎｄｖｌｐｎｆｍｕｔｒｇｒｓｓｃＭＤＲｉｅａｏａｅｎｍａｃｌ．Ｍｅｈｄｉａ１ｎｈｐｔｅｉｏｅｓｒ２／ｄ１７２／ｄ２ＮｉＭＰｄ７１ｍ和７１ｍ细胞可致ＭＲ１ＡＡＤ一表达降低，增加了其对化疗药物的敏感性。
结论ＥＰＩＭＭＲＮ是参与肝癌细胞７２多药耐药且为调节多药耐药的重要分子。７１

Alda-1_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Alda–1 is a potent ALDH2 agonist, which significantly improves ALDH2 activity.In Vivo: Alda–1 treatment results in a significant decrease of 4–HNE–protein content in the plasma of apoE -/- mice. Alda–1administration leads to a slight increase in gene expression related to neurogenesis (Nog ), mitochondrial biogenesis (CYTB , ND1),and apoptosis (Bax , Gsk3b ) in the Hp of apoE -/- mice. Alda–1 administration leads to 2 and 10 differentially expressed proteins in theFCx and Hp of apoE -/- mice, respectively [1]. Alda–1 (1.5 mg/kg, b.w., i.p.) administration significantly increases the climbing time,tends to reduce the immobility time and increases the swimming time of the prenatally stressed rats in the forced swim test.Moreover, treatment of prenatally stressed rats with Alda–1 significantly increases number of entries into the open arms of the maze and the time spent therein, as assessed by elevated plus–maze test [2]. Alda–1 (8.5 mg/kg, i.p.) with glucose significantly lowers 4–HNE and FJB–positive cells in the cerebral cortex of Alda–1–treated rats than in DMSO–treated rats 24 h after glucose administration [3]. Alda–1 (10 mg/kg per day) treatment prevents aldehydic overload, mitochondrial dysfunction and improves ventricular function in post–MI cardiomyopathy rats [4].PROTOCOL (Extracted from published papers and Only for reference)Cell Assay:[2]Spleen cells (4×106 cells/mL) are stimulated by optimal concentrations of concanavalin A (Con A; 2.5μg/mL and 0.6 μg/mL) and lipopolysaccharide (LPS, 5 μg/mL) and are incubated in 96–well plates at final volume of 0.2mL for 72 h. Cell proliferation is determined by adding 0.5 μCi of [3H]–thymidine per well at 16 h before the end of the incubation.The cultures are harvested with an automatic cell harvester, and [3H] thymidine incorporation is assessed using a liquid scintillationcounter.Animal Administration: Alda–1 is dissolved in 1 mL/kg b.w. DMSO/water 50/50.[2]After behavioral verification at three months of age,the animals are divided into the following four groups: control, control + Alda–1, prenatally stressed and prenatally stressed + Alda–1(6 animals per group). Alda–1 injections are given intraperitoneally (i.p.) once daily at a dose of 1.5 mg/kg b.w. (dissolved in 1 mL/kg b.w. DMSO/water 50/50) for 14 days. At the same time, the control and prenatally stressed rats receive 1 mL/kg b.w. DMSO/water 50/50. The injections of Alda–1 and vehicle are given between 10 a.m and 11 a.m. In the last five days of Alda–1 treatment the behavioral parameters in the elevated plus maze test and then in the forced swim test are measured.References:[1]. Stachowicz A, et al. Proteomic Analysis of Mitochondria–Enriched Fraction Isolated from the Frontal Cortex and Hippocampus of Apolipoprotein E Knockout Mice Treated with Alda–1, an Activator of Mitochondrial Aldehyde Dehydrogenase (ALDH2). Int J Mol Sci.[2]. Stachowicz A, et al. The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda–1 on the behavioral and biochemical disturbances in animal model of depression. Brain Behav Immun. 2016 Jan;51:144–53.Product Name:Alda–1Cat. No.:HY-18936CAS No.:349438-38-6Molecular Formula:C 15H 11Cl 2NO 3Molecular Weight:324.16Target:Aldehyde Dehydrogenase (ALDH)Pathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 51 mg/mL[3]. Ikeda T, et al. Effects of Alda–1, an Aldehyde Dehydrogenase–2 Agonist, on Hypoglycemic Neuronal Death. PLoS One. 2015 Jun 17;10(6):e0128844.[4]. Gomes KM, et al. Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post–myocardial infarction cardiomyopathy: benefits of Alda–1. Int J Cardiol. 2015 Jan 20;179:129–138.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。